A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ability to mitigate brain damage and improve cognitive functions in mouse models. A forthcoming clinical trial aims to test its efficacy in humans.
Most current treatments for Alzheimer’s disease focus on addressing amyloid plaques and tau tangles in the brain. However, researchers from Mass General Brigham and Washington University School of Medicine in St. Louis have identified a groundbreaking alternative: Xenon gas.
Their study demonstrated that inhaling Xenon gas reduced neuroinflammation, minimized brain atrophy, and promoted protective neuronal states in mouse models of Alzheimer’s disease. These findings, published today (January 15) in Science Translational Medicine, have paved the way for a phase 1 clinical trial in healthy volunteers, set to begin in early 2025.
Groundbreaking Research and Clinical Trials
“It is a very novel discovery showing that simply inhaling an inert gas can have such a profound neuroprotective effect,” said senior and co-corresponding author Oleg Butovsky, PhD, of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital (BWH), a founding member of the Mass General Brigham healthcare system. “One of the main limitations in the field of Alzheimer’s disease research and treatment is that it is extremely difficult to design medications that can pass the blood-brain barrier—but Xenon gas does. We look forward to seeing this novel approach tested in humans.”
“It is exciting that in both animal models that model different aspects of Alzheimer’s disease, amyloid pathology in one model and tau pathology in another model, that Xenon had protective effects in both situations,” said senior and co-corresponding author David M. Holtzman, MD, from Washington University School of Medicine in St. Louis.
The Science Behind Xenon’s Effects
The exact causes of Alzheimer’s disease remain unclear, and there is currently no cure. More effective treatments are urgently needed. Alzheimer’s is marked by the buildup of proteins in the brain, such as tau and amyloid, which disrupt nerve cell communication. Over time, this leads to progressive brain damage, neuronal loss, and ultimately, death.
Microglia, the brain’s primary immune cells, act as the brain’s first line of defense, responding to any disruptions and playing a crucial role in maintaining brain function throughout life. However, when microglia become dysregulated, they contribute significantly to the progression of Alzheimer’s disease. Research from Dr. Butovsky’s lab has developed a method to study microglial responses to neurodegeneration, revealing that certain microglial phenotypes can be modulated to provide protective effects against Alzheimer’s.
In this study, mouse models of Alzheimer’s disease were treated with Xenon gas that has been used in human medicine as an anesthetic and as a neuroprotectant for treating brain injuries. Xenon gas penetrates the blood-brain barrier, passing from the bloodstream directly into the fluid surrounding the brain. The team found that Xenon gas inhalation reduced brain atrophy and neuroinflammation and improved nest-building behaviors in the Alzheimer’s disease mouse models. It also induced and increased a protective microglial response that is associated with clearing amyloid and improving cognition. Together, these findings identify the promising potential of Xenon inhalation as a therapeutic approach that could modify microglial activity and reduce neurodegeneration in Alzheimer’s disease.
Future Directions and Clinical Potential
The clinical trial at Brigham and Women’s Hospital, which will initially only enroll healthy volunteers, is set to begin in the next few months.
As early phases of the clinical trial get underway to establish safety and dosage, the research team plans to continue to study the mechanisms by which Xenon gas achieves its effects in addition to its potential for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of neurons. The team is also devising technologies to help use Xenon gas more efficiently as well as potentially recycle it.
“If the clinical trial goes well, the opportunities for the use of Xenon gas are great,” said co-author Howard Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at BWH and principal investigator of the upcoming clinical trial. “It could open the door to new treatments for helping patients with neurologic diseases.”
Reference: “Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy” by Wesley Brandao, Nimansha Jain, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Xin Bao, Javier R. Serrano, Eric Tycksen, Ana Durao, Jen-Li Barry, Caroline Baufeld, Dilansu Guneykaya, Xiaoming Zhang, Alexandra Litvinchuk, Hong Jiang, Neta Rosenzweig, Kristen M. Pitts, Michael Aronchik, Taha Yahya, Tian Cao, Marcelo Kenzo Takahashi, Rajesh Krishnan, Hayk Davtyan, Jason D. Ulrich, Mathew Blurton-Jones, Ilya Ilin, Howard L. Weiner, David M. Holtzman and Oleg Butovsky, 15 January 2025, Science Translational Medicine.
DOI: 10.1126/scitranslmed.adk3690
Authorship: In addition to Butovsky and Weiner, Mass General Brigham authors include Wesley Brandao, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Ana Durao, Jen-Li Barry, Caroline Baufeld, Dilansu Guneykaya, Xiaoming Zhang, Neta Rosenzweig, Kristen M. Pitts, Michael Aronchik, Taha Yahya, Tian Cao, Marcelo Kenzo Takahashi, Rajesh Krishnan, Additional authors include Nimansha Jain, Xin Bao, Javier R. Serrano, Eric Tycksen, Alexandra Litvinchuk, Hong Jiang, Hayk Davtyan, Jason D. Ulrich, Mathew Blurton-Jones, Ilya Ilin, and David M. Holtzman.
Disclosures: Butovsky, Ilin, Weiner, Yin, and Brandao are co-inventors on patent no. 17/914,061 (held by Brigham and Women’s Hospital and General Biophysics) for using Xe to treat neurodegenerative diseases. Butovsky is co-founder and is on the scientific advisory board of Glial Therapeutics and GliaX; collaborates with GSK and Regulus Therapeutics; has research funding from Sanofi, GSK; and consults for/has received honoraria from UCB, Camp4, Ono Pharma USA, General Biophysics. Holtzman co-founded and is on the scientific advisory board of C2N Diagnostics. Holtzman is on the scientific advisory board of Denali, Genentech, and Cajal Neurosciences and consults for Asteroid Therapeutics. Blurton-Jones co-founded and is on the scientific advisory board of NovoGlia Inc. Ilin is the founder and CEO of General Biophysics LLC.
Funding: This study was funded by National Institutes of Health (NIH) (STTR R41AG073059, R01 AG051812 R01 AG054672, R01 NS088137 R01 AG075509, RF1 NS090934, P30 AG066519, U19 AG06970101); Cure Alzheimer Fund; Massachusetts Center for Alzheimer Therapeutic Science (MassCATS); BrightFocus Foundation 2020A016806; Alzheimer’s Association research fellowship AARF-21-846786; National Multiple
Sclerosis Society FG-2108-38372; Department of Defense W81XWH-22-1-0945

News
Superbugs Are Losing to Science, Light, and a Little Spice
Texas A&M researchers have found that curcumin, when activated by light, can weaken antibiotic-resistant bacteria, restoring the effectiveness of conventional antibiotics. Curcumin: A Surprising Ally Against Superbugs In 2017, a woman admitted to a [...]
New Research Shatters the Perfect Pitch Myth
For decades, people believed absolute pitch was an exclusive ability granted only to those with the right genetics or early music training. But new research from the University of Surrey proves otherwise. It’s been [...]
Why Some Drinkers Suffer Devastating Liver Damage While Others Don’t
A study from Keck Medicine of USC found that heavy drinkers with diabetes, high blood pressure, or a large waistline are up to 2.4 times more likely to develop advanced liver disease. These conditions may amplify [...]
“Good” Cholesterol Could Be Bad for Your Eyes – New Study Raises Concerns
‘Good’ cholesterol may be linked to an increased risk of glaucoma in individuals over 55, while, paradoxically, ‘bad’ cholesterol may be associated with a lower risk. These findings challenge conventional beliefs about factors that [...]
Reawakening Dormant Nerve Cells: Groundbreaking Neurotechnology Restores Motor Function
A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and improving movement. In a pilot clinical trial, three patients who received spinal cord stimulation for one [...]
AI’s Energy Crisis Solved? A Revolutionary Magnetic Chip Could Change Everything
AI is evolving at an incredible pace, but its growing energy demands pose a major challenge. Enter spintronic devices—new technology that mimics the brain’s efficiency by integrating memory and processing. Scientists in Japan have [...]
Nanotechnology for oil spill response and cleanup in coastal regions
(Nanowerk News) Cleaning up after a major oil spill is a long, expensive process, and the damage to a coastal region’s ecosystem can be significant. This is especially true for the world’s Arctic region, [...]
The Role of Nanotechnology in Space Exploration
Nanotechnology, which involves working with materials at the atomic or molecular level, is becoming increasingly important in space exploration. By improving strength, thermal stability, electrical conductivity, and radiation resistance, nanotechnology is helping create lighter, more [...]
New Study Challenges Beliefs About CBD in Pregnancy, Reveals Unexpected Risks
CBD is gaining popularity as a remedy for pregnancy symptoms like nausea and anxiety, but new research suggests it may not be as safe as many believe. A study from McMaster University found that [...]
Does COVID increase the risk of Alzheimer’s disease?
Scientists discover that even mild COVID-19 can alter brain proteins linked to Alzheimer’s disease, potentially increasing dementia risk—raising urgent public health concerns. A recent study published in the journal Nature Medicine investigated whether both mild and [...]
New MRI Study Reveals How Cannabis Alters Brain Activity and Weakens Memory
A massive new study sheds light on how cannabis affects the brain, particularly during cognitive tasks. Researchers analyzed over 1,000 young adults and found that both heavy lifetime use and recent cannabis consumption significantly reduced brain [...]
How to Assess Nanotoxicity: Key Methods and Protocols
With their high surface area and enhanced physicochemical properties, nanomaterials play a critical role in drug delivery, consumer products, and environmental technologies. However, their nanoscale dimensions enable interactions with cellular components in complex and [...]
Nanotech drug delivery shows lasting benefits, reducing need for repeat surgeries
A nanotechnology-based drug delivery system developed at UVA Health to save patients from repeated surgeries has proved to have unexpectedly long-lasting benefits in lab tests – a promising sign for its potential to help human patients. [...]
Scientists Just Found DNA’s Building Blocks in Asteroid Bennu – Could This Explain Life’s Origins?
Japanese scientists detected all five nucleobases — building blocks of DNA and RNA — in samples returned from asteroid Bennu by NASA’s OSIRIS-REx mission. NASA’s OSIRIS-REx mission brought back 121.6 grams of asteroid Bennu, unveiling nitrogen-rich organic matter, including DNA’s essential [...]
AI-Designed Proteins – Unlike Any Found in Nature – Revolutionize Snakebite Treatment
Scientists have pioneered a groundbreaking method to combat snake venom using newly designed proteins, offering hope for more effective, accessible, and affordable antivenom solutions. By utilizing advanced computational techniques and deep learning, this innovative [...]
New nanosystem offers hope for improved diagnosis and treatment of tongue cancer
A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and treatment of tongue squamous cell carcinoma (TSCC). By harnessing gold nanoparticles coupled with the HN-1 peptide, [...]